Northwest Biotherapeutics (NWBO) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Northwest Biotherapeutics (NWBO) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 45.47% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 91.31% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Northwest Biotherapeutics | 272.75 Mn | 270.97 Mn | - | 32.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.48% |
| Dec 31, 2025 | 26.91% |
| Sep 30, 2025 | 6.12% |
| Jun 30, 2025 | 18.71% |
| Mar 31, 2025 | -11.32% |
| Dec 31, 2024 | -29.25% |
| Sep 30, 2024 | -85.89% |
| Jun 30, 2024 | -83.23% |
| Mar 31, 2024 | -66.06% |
| Dec 31, 2023 | 62.90% |
| Sep 30, 2023 | 50.15% |
| Jun 30, 2023 | 36.35% |
| Mar 31, 2023 | -83.78% |
| Dec 31, 2022 | -87.54% |
| Sep 30, 2022 | -73.95% |
| Jun 30, 2022 | -416.10% |
| Mar 31, 2022 | 12.12% |
| Dec 31, 2021 | 222.86% |
| Sep 30, 2021 | -19.34% |
| Jun 30, 2021 | 29.63% |